Alternative Pharmaceutical Innovation Models in Competitive Markets: A Collaborative Approach to Develop a Novel Drug...

Area of Science:

• Pharmaceutical Innovation
• Drug Development
• Global Health

Background:

• Traditional pharmaceutical innovation models struggle with diseases lacking market incentives.
• The feasibility of alternative models in profitable markets remains underexplored.

Purpose of the Study:

• To analyze the development of ravidasvir, a novel hepatitis C drug, within a highly profitable market.
• To assess the viability of alternative innovation models involving non-traditional partners.

Main Methods:

• Qualitative research, including literature reviews and semi-structured interviews.
• Analysis using a novel conceptual framework focusing on actors, resources, organizational practices, and outcomes.

Main Results:

• Ravidasvir was developed without major pharmaceutical companies, utilizing a collaborative network of public and private partners from low- and middle-income countries.
• The drug proved highly effective, easy-to-use, and affordable, contributing to capacity strengthening.
• Challenges included strategic behavior from competing firms and external conditions impacting public health impact.

Conclusions:

• Alternative innovation models can be successful in profitable markets by leveraging diverse partnerships.
• Lessons learned can guide future drug development for commercially attractive therapeutic areas.
• Collaboration among non-traditional partners is key to addressing global health needs.